Article type: Letter to Editor
Article
title: Oligomannate
and aducanumab: novel drugs for alzheimer disease
Journal: Ibnosina
Journal of Medicine and Biomedical Sciences
Year: 2020
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
AD is the most common type of dementia and may affect
more than half of the population. In addition, it is among the most frequent
causes of death because contributes to an increased risk of infection. AD is
considered a neurodegenerative disease and it interferes in the spheres of
cognitive functioning such as memory, attention, executive functioning, and
language. The onset of AD typically is associated with age and normally
presents with short-term memory loss and executive functioning. Functional and structural
neuroimaging in AD are promising techniques to supplement the diagnosis and
monitor the clinical course of the disease. The management of AD to date is
only symptomatic including cholinesterase inhibitors and Partial N-Methyl
D-Aspartate antagonists. In this context, donepezil (Aricept) was approved in
1996 and memantine in 2003 by the Food and Drug Administration. Here, our
objective is to provide a comprehensible overview of two new drugs for AD.
These medications are important because they have new promising mechanisms and
are derived from different substances.
Keywords: Alzheimer disease, oligomannate, gv-971, aducanumab
Full text available at:
DOI
10.4103/ijmbs.ijmbs_114_20
Citation
Rissardo
JP, Caprara AL. Oligomannate and aducanumab: novel
drugs for alzheimer disease. Ibnosina J Med Biomed Sci 2020;12:327-8